SOX17 expression and its down-regulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma.
Adenocarcinoma
/ genetics
Adenocarcinoma in Situ
/ genetics
Cervix Uteri
/ pathology
DNA Methylation
Down-Regulation
Female
Humans
Papillomaviridae
/ physiology
Papillomavirus Infections
/ genetics
Promoter Regions, Genetic
SOXB1 Transcription Factors
/ genetics
SOXF Transcription Factors
/ genetics
Uterine Cervical Neoplasms
/ genetics
SOX17
SOX2
cervical (pre)neoplasia
keratins
reserve cells
squamocolumnar junction
transformation zone
uterine cervix
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
11
07
2019
accepted:
20
08
2019
pubmed:
25
8
2019
medline:
27
10
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
SOX17 expression has not been studied in glandular lesions of the uterine cervix like adenocarcinoma in situ (AIS) and invasive adenocarcinomas (AdC), whereas SOX17 promoter CpG island methylation has been reported. Therefore, the aim of this study was to relate the topographical distribution of SOX17 expression and SOX17 methylation status to each other, and to SOX2 expression, human papillomavirus (HPV) type, and physical status of the virus. Immunohistochemistry was used in 45 cases to assess expression of SOX17 and SOX2. SOX17 promoter methylation was determined in 25 cases by means of bisulphite conversion and methylation-specific polymerase chain reaction. SOX17 and SOX2 showed a mutually exclusive expression pattern in normal epithelium, with a sharp delineation in the squamocolumnar junction. SOX17 was found in endocervical columnar and reserve cells, whereas SOX2 was exclusively found in squamous epithelium. In both glandular lesions and cases with coexisting glandular and squamous intraepithelial components, a complex combination of SOX17 and SOX2 expression patterns was seen and mutually exclusive expression was lost. Frequently, gain of expression of SOX2 was found and expression of SOX17 was lost. Methylation of the CpG island in the SOX17 promoter was shown to be strongly associated with loss of expression of SOX17 (P = 0.0016). In this study, we show for the first time a direct correlation between the topographical distribution of SOX17 expression and the methylation status of its gene promoter. This explains the heterogeneity of SOX17 expression in the glandular lesions of the cervix. No correlation was found between HPV type and physical status of the virus on the one hand and methylation status on the other.
Identifiants
pubmed: 31444787
doi: 10.1111/his.13980
pmc: PMC7027543
doi:
Substances chimiques
SOX17 protein, human
0
SOX2 protein, human
0
SOXB1 Transcription Factors
0
SOXF Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-393Informations de copyright
© 2019 The Authors. Histopathology published by John Wiley & Sons Ltd.
Références
J Pathol. 2006 Dec;210(4):412-9
pubmed: 17054308
Gynecol Oncol. 2011 Oct;123(1):116-22
pubmed: 21726894
Development. 2004 Jul;131(13):3069-80
pubmed: 15163629
J Clin Pathol. 2005 Jun;58(6):671
pubmed: 15917428
Obstet Gynecol. 1983 Jul;62(1):117-27
pubmed: 6856213
Br J Cancer. 2006 Aug 7;95(3):331-8
pubmed: 16847471
J Clin Pathol. 1986 Jan;39(1):22-8
pubmed: 3950029
Pathologe. 2011 Nov;32 Suppl 2:242-54
pubmed: 21909794
Curr Opin Genet Dev. 2017 Oct;46:24-36
pubmed: 28662445
Hum Pathol. 2012 Dec;43(12):2255-65
pubmed: 22809729
Nat Rev Cancer. 2007 Jan;7(1):11-22
pubmed: 17186016
Hum Pathol. 2010 Oct;41(10):1438-47
pubmed: 20709360
Am J Pathol. 1992 Mar;140(3):601-12
pubmed: 1372156
Histopathology. 2020 Feb;76(3):383-393
pubmed: 31444787
PLoS One. 2014 Jan 28;9(1):e87092
pubmed: 24489842
J Pathol. 2008 May;215(1):21-30
pubmed: 18348160
PLoS One. 2014 Mar 19;9(3):e91905
pubmed: 24647315
Medicine (Baltimore). 2015 Mar;94(11):e637
pubmed: 25789956
Cancer Res. 2008 Jan 1;68(1):307-13
pubmed: 18172324
Cancer Res. 2008 Apr 15;68(8):2764-72
pubmed: 18413743
Histopathology. 2007 Apr;50(5):629-35
pubmed: 17394499
Hum Pathol. 2005 Feb;36(2):154-61
pubmed: 15754292
Trends Microbiol. 2011 Mar;19(3):114-20
pubmed: 21216598
Am J Surg Pathol. 2005 Dec;29(12):1609-14
pubmed: 16327433
Int J Cancer. 2015 Dec 15;137(12):2858-68
pubmed: 26096203
Lancet. 2007 Sep 8;370(9590):890-907
pubmed: 17826171
Int J Cancer. 2005 Jun 20;115(3):419-28
pubmed: 15688369
Eur J Cancer. 2014 Jan;50(1):85-98
pubmed: 24054023
Br J Cancer. 2003 Sep 1;89(5):886-90
pubmed: 12942122
Cell Oncol. 2004;26(5-6):291-9
pubmed: 15623939
Epigenetics. 2010 Nov-Dec;5(8):743-9
pubmed: 20716954
Am J Clin Pathol. 2017 Sep 1;148(3):264-273
pubmed: 28821199
J Pathol. 2015 Jul;236(3):265-71
pubmed: 25782708
Mod Pathol. 2014 Apr;27(4):621-30
pubmed: 24051697
Int J Gynecol Pathol. 2007 Oct;26(4):463-8
pubmed: 17885499
Int J Gynecol Pathol. 2010 Jul;29(4):378-85
pubmed: 20567153
Trends Mol Med. 2009 Jun;15(6):245-53
pubmed: 19457719
Nat Rev Dis Primers. 2016 Dec 01;2:16086
pubmed: 27905473
Hum Pathol. 2013 Nov;44(11):2410-8
pubmed: 23968641
Int J Gynecol Pathol. 2017 Nov;36(6):517-522
pubmed: 28639968
Cell Death Dis. 2018 Jul 3;9(7):741
pubmed: 29970906
J Invest Dermatol. 2014 Dec;134(12):2957-2966
pubmed: 24999589
J Med Virol. 2013 Aug;85(8):1386-93
pubmed: 23765775
Vaccine. 2012 Nov 20;30 Suppl 5:F12-23
pubmed: 23199955